<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6704">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112903</url>
  </required_header>
  <id_info>
    <org_study_id>15947A</org_study_id>
    <secondary_id>2014-000121-20</secondary_id>
    <nct_id>NCT02112903</nct_id>
  </id_info>
  <brief_title>Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women</brief_title>
  <official_title>Interventional, Randomised, Double-blind 4-way Crossover Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea,
      vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following
      single oral doses of three modified-release (MR) capsules with differently coated multiple
      particles compared to one immediate-release (IR) tablet.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Gastro-intestinal tolerability (nausea) measured with 11-point Numerical Rating Scale</measure>
    <time_frame>Up to 24 hours post-dose in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastro-intestinal tolerability (abdominal pain) measured with 11-point Numerical Rating Scale</measure>
    <time_frame>Up to 24 hours post-dose in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastro-intestinal tolerability (abdominal discomfort) measured with 11-point Numerical Rating Scale</measure>
    <time_frame>Up to 24 hours post-dose in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, severity and duration of reported gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort and abdominal pain)</measure>
    <time_frame>Up to 72 hours post-dose in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the vortioxetine plasma concentration-time curve from zero to 72 hours post-dose (AUC0-72h)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of vortioxetine</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Nominal time corresponding to the occurrence of Cmax (tmax)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Women</condition>
  <arm_group>
    <arm_group_label>Encapsulated vortioxetine IR tablet, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 5.5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 6.0)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 7.0)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encapsulated vortioxetine IR tablet, 20 mg</intervention_name>
    <arm_group_label>Encapsulated vortioxetine IR tablet, 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine MR capsule 20 mg (pH 5.5)</intervention_name>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 5.5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine MR capsule 20 mg (pH 6.0)</intervention_name>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 6.0)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine MR capsule 20 mg (pH 7.0)</intervention_name>
    <arm_group_label>Vortioxetine MR capsule 20 mg (pH 7.0)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women ≥18 and ≤45 years of age with a body mass index (BMI) of &gt;18.5 and
             &lt;30.0 kg/m2.

          -  Women will be of child-bearing potential with a confirmed non-pregnant and
             non-lactating status.

        Other protocol-defined Inclusion and Exclusion Criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GB801</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
